ABOUT ROCKETVAX
Rocketvax AG is a Swiss biotech company focussing on the development of next-generation vaccines based on live-attenuated virus technology. With its lead candidates, RVX-sCPD9 and RVX-OTS, Rocketvax AG aims to develop promising vaccines to prevent infection with existing and novel SARS-CoV-2 variants.
Rocketvax AG is part of the Swiss Rockets group of companies, a leading biotech incubator situated in Switzerland
ABOUT ROCKETVAX
SCIENCE
AT THE CORE
LEADERSHIP
EXCELLENCE
DRIVEN BY
INNOVATION
PROPRIETARY
IP
* Manufacturing Process for RVX-sCPD9 locked and ready for GMP
TECHNOLOGY:
ROCKETVAX SARS-CoV-2 ACCINE PLATFORM
Springboarding on existing expertise towards developing universal concepts for live-attenuated vaccines - Rational genetic design for generating attenuated viruses - Concepts expected to be applicable to a wide variety of viruses, including the following:
CORONAVIRUSES
COVID-19
MERS-COV
FLAVIVIRUSES
INFLUENZA
PNEUMOVIRUSES
ALPHAVIRUSES
HERPES
LATEST NEWS
Download Our
Company Presentation
your name
your email
organization name